When Ipsen announced last week that it wanted in on Exelixis’ Cabometyx for thyroid cancer, the company pegged that move to the oncology drug’s promising late-stage trial results. Now, Exelixis is offering up more details of that very trial. For a phase 3 study up for presentation at the virtual American Society of Clinical Oncology meeting, investigators… Read More »
The first data from the large implementation study of HIV pre-exposure prophylaxis (PrEP) in England, The IMPACT trial, were presented at the joint British HIV Association and British Association of Sexual Health and HIV conference this week. Chief Investigator, Dr Ann Sullivan of London’s Chelsea and Westminster Hospital, told the conference that although there were… Read More »
The Food and Drug Administration (FDA) approved inexpensive, at-home coronavirus tests for over-the-counter sales this week, adding a potentially powerful weapon to the nation’s pandemic-fighting arsenal that experts say will likely still be needed despite increasing numbers of vaccinated Americans. One of them is Michael Mina, assistant professor of epidemiology, who has called on federal… Read More »